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Antigens with aromatic amino groups can be conjugated to proteins by a diazo
bond. This property was used to synthesise an antigen-biotin conjugate using
bovine serum albumin (BSA) as a bridge, and tested this conjugate in an
enzymoimmunoassay for clenbuterol detection. The assay included a highly
specific antibody and the biotin-avidin amplification system. Its coefficient of
variation was lower than 20% in the range of 1008000 pg per well and the limit
of detection was 6.4 pg. The synthesis of clenbuterolBSAbiotin conjugate was
reproducible, the reaction product easily purified and the amplification capacity
could be set by adjusting the clenbuterol:biotin ratio.
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1. Introduction
Aromatic amino groups from an antigen can be diazotised with nitrous acid to form
diazonium compounds. The diazonium group will react with phenolic, imidazole and
amino side chains of a protein to form a diazo bond. This paper proposes to use this
method for the construction of a conjugate of clenbuterol, a well known anabolic
that is administered to cattle to improve meat rate and reduce animal fat (Smith &
Paulson, 1997; Smith, 1998; Kuiper, Noordam, van Dooren-Flipsen, Schilt, & Roos,
1998; Mitchell & Dunnavan, 1998). Clenbuterol is a ß-adrenergic agonist that mimics
the activity of adrenaline and noradrenaline (Fiems, 1987; Mersmann, 1998). It is
used for the treatment of bronchial diseases but, because it has also been used
illegally as a growth-promoting agent in meat production, it is being extensively
controlled as a veterinary drug residue in food safety. The residues of clenbuterol
which accumulate in animal tissues can cause symptoms of acute poisoning in
humans (Brambilla et al., 2000; Kuiper, Noordam, Dooren-Flipsen, Schilt, & Roos,
1998; Meyer & Rinke, 1991; Mitchell & Dunnavan, 1998).
Detection limits for residue control must be within the range of ng per tissue
gram. This can be achieved by HPLC or capillary electrophoresis with electro-
chemical detection (Blanchflower, Hewitt, Cannavan, Elliott, & Kennedy, 1993;
Boyd, O’Keefe, & Smyth, 1996; Chen, Wang, Duan, Chen, & Chen, 2005; De Wasch,
De Brabander and Courtheyn, 1998; Gleixner, Sauerwein, & Meyer, 1996;
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Hooijerink, Schilt, Haasnoot, & Courtheijn, 1991; Lin, Tomlinson, & Satzger, 1997;
Polettini et al., 1995), highly sensitive immunoassays or HPLC or GC with MS
detection (Abukhalaf et al., 2000; Blanca et al., 2005; Guy, Savoy, & Stadler, 1999;
He, Su, Zeng, Liu, & Huang, 2007). These instrumental techniques, although
selective and sensitive with low detection methods, are expensive and require a big
amount of sample. For these reasons, immunoassays are the screening methods of
choice in determining illegal use.
The first enzymoimmunoassay (EIA) for clenbuterol was developed by
Yamamoto and Iwata in 1982 (Yamamoto & Iwata, 1982). Since then, many
other EIAs, with a wide range of use, including enzymeclenbuterol conjugate, have
been reported (Bucknall et al., 1993; Degand, Bernes-Duyckaerts, & Maghuin-
Rogister, 1992; Haasnoot, Stouten, Schilt, & Hooijerink, 1998; Meyer & Rinke,
1991; Posyniak, Zmudzki, & Niedzielska, 2003; Ren, Zhang, Chen, & Yang, 2009;
Sauer, Pickett, & Mac Kenzie, 1993). Further, publications have described
immunobiosensor methods for screening, with immobilised antigen or antibody
(Chen & Li, 2007; Johansson & Hellenäs, 2001; Johansson & Hellenäs, 2003;
Traynor, Crooks, Bowers & Elliott, 2003). Recently, electrochemical immunosensors
have gained growing attention because they combine the high specificity of
traditional immunoassay methods with the low detection limits and low expenses
of electrochemical measurement system (He, Wang, Zhang, & Yang, 2009).
Although the development of a b-agonist-biotin conjugate, and its successful use
in a clenbuterol EIA has been published (Rinke & Dürsch, 1991; Yamamoto &
Iwata, 1982) to our knowledge, there is no clenbuterol-biotin conjugate previously
described.
The objective has been developed an antigen-biotin conjugate using a protein as a
bridge. Clenbuterol and EIA were used to characterise this conjugate, which can be
of general application for most antigens with aromatic amino groups, and other
immunoassay designs.
2. Experimental
2.1. Preparation and purification of the protein-clenbuterol conjugate
Conjugation of bovine serum albumin (BSA) to clenbuterol was performed by
the diazotised method of Yamamoto and Iwata(1982). Briefly, 3 mg of NaNO2
dissolved in 200 mL of distilled water was added drop-wise to 3 mg of clenbuterol
HCl in 400 mL of water and 100 mL of 1N HCl, under dark conditions at 48C, with
continuous stirring. After 30 min, unreacted NO2 was eliminated by the addition of
7 mg of ammonium sulfamate in 140 mL of water until there were no more bubbles.
Diazo-clenbuterol was detected by a yellow-coloured reaction by adding 50 mL of
N,N-dimethyl aniline to 10 mL of the reaction mixture. Then, 150 mL of the diazo-
derivate was added drop-wise to 40, 6, 3 and 0 mg of BSA in 200 mL of 0.1 M
pH 7.5 sodium phosphate buffer. The pH was adjusted to 7 with 1N NaOH (about
15 mL). The preparation was allowed to stand overnight in darkness at 58C. Finally,
the clenbuterol-BSA (clen-BSA) conjugate was purified by centrifugal filter devices
with a YM-30 membrane of regenerated cellulose (Centricom, Millipore), which
provides concentration and desalting of macromolecules over a 30,000 Da molar
weight. The filtrate was tested by HPLC-UV 280 nm, with a C18 column (Vydac,
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5 mm, 15045 mm) and acetonitrile:buffer (20 mM KH2PO4, pH 4.4) (1:4) at
1mL/min. The optimum proportion of diazo-clenbuterol to BSA for the coupling
reaction was established as 0.5 mg of diazo-clenbuterol to 6 mg of BSA, by testing
the reduction of free diazo-clenbuterol in the chromatogram of the filtrate.
To obtain a high molecular weight immunogen for antibody production, the
diazo-clenbuterol was coupled to human serum albumin (HSA) using the same
methodology.
2.2. Preparation of the clenbuterol-BSA-biotin (CBB) conjugate
To obtain a CBB conjugate, clen-BSA was labelled using a common procedure to
couple biotin residues to proteins. Fresh solution of 10 mg/ml N-hydroxysuccinimi-
do-biotin (NHS-Biotin) (from Pierce) in dimethyl sulfoxide was prepared and
different volumes of this solution containing: 300, 100, 35 and 10 mg, were added
drop-wise on100 mg of clem-BSA in 110 mL of 0.1 M sodium borate buffer, pH 8.8.
After incubation in darkness, at room temperature for 2 to 3 h, the reaction mixture
was allowed to stand at 48C overnight. The reaction was stopped by the addition of
30 mL of 1M NH4Cl. The biotinylated clen-BSA (CBB) was then dialysed against
phosphate buffered saline (PBS) at 48C overnight.
2.3. Immunisation. IgG fraction purification from antiserum
Antibody against clenbuterol (anti-clen) was produced in rabbits by intradermal
immunisation. The first dose of 0.5 mg clenbuterol-HSA conjugate (clen-HSA) was
administered to rabbits in complete Freund’s adjuvant, and the booster doses of
0.2 mg of the immunogen in incomplete Freund’s adjuvant at two-week intervals.
After the fifth booster, 12 mL of blood was taken from the ear vein, and tested for
clenbuterol antibodies by immunodiffusion in agar, using clen-HSA and clen-BSA as
antigens in the presence of an excess of BSA to block any cross-reaction to serum
albumin. This experiment was performed in compliance with the relevant laws and
institutional guidelines approved by the authorities of the Instituto de Biologı́a y
Medicina Experimental (IByME), Buenos Aires, Argentina.
In order to obtain the IgG fraction from the serum, a column was prepared with
200 mL of protein A immobilised on Sepharose 4B (from Sigma) suspension and
washed with five volumes of 5% BSA in PBS. The column was then loaded with
800 mL of serum diluted with 50 mL of 1M Tris buffer, pH 8.5. After washes with
2 ml of the same buffer, the IgG fraction was eluted with 800 mL of HCl pH 2.5
NaCl 100 mM. At this pH, antibodies suffer Fab denaturalisation. The eluted
fraction was diluted (1:2) in washing buffer and stored at 48C. Total protein
concentration was calculated by UV absorbance at 280 nm.
2.4. Competitive enzymoimmunoassay
The anti-clen was denaturalised by lowering the pH to 2.5 with HCl and NaCl
100 mM for 10 min, readjusting to pH 8 with 0.1M sodium phosphate buffer.
Polyestyrene strips Maxisorp (from Nunc) were coated by incubation with 100 mL
of the antibody solution at different concentrations in the same buffer per well
and incubated at room temperature overnight. After washing with PBS 0.02%
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Tween 20, the wells were blocked with 400 mL 5% BSA in PBS, at room
temperature for 1 h. The strips coated with anti-clen could be stored dried at 48C
without loss of activity.
For the assay, 100 mL of samples or clenbuterol standard solutions (100, 20, 4,
0.8, 0.16, 0.032, 0.0064 and 0 ng/100 mL) in 0.1% BSA and 0.02% Tween 20 in PBS
were added to coated wells with 100 mL of CBB at a proper concentration for each
experiment in the same buffer, and incubated at room temperature for 2 h. After
extensive washing, the wells were incubated with 100 mL of Extr-Avidin Alkaline
Phosphatase (EAP, Sigma), at the recommended dilution (1:2000) in PBS 0.1% BSA,
at room temperature for 1 h, and the presence of the enzyme was detected by the
phosphatase reaction with 100 mL of 1 mg/ml p-nitrophenylphosphate in 1M
diethanolamine pH 9.8, 0.5 mM MgCl2 (pNPP) at room temperature. The
absorbance was read at 405 nm after 30 min. The reaction could be stopped by
the addition of 100 mL of 1M NaOH.
2.5. Calculation of results
The software package I-Smart 2.0 (Packard Bioscience Company) was used to fit the
four-parameter logistic curve:
Y ¼ ðA  DÞ=½1 þ ðX=CÞB þ D
where A is the absorbance at zero concentration of clenbuterol and D is response at
infinite concentration (clenbuterol 100 ng/100mL). C represents the half maximal
inhibitory concentration (IC50), a measure of the effectiveness of a compound in
inhibiting the antibody bound and the concentration resulting in the response which
is halfway between A and D.
The precision profile gives the relation of standard deviation (SD) of concentra-
tion (DC) or coefficient of variation (CV) of the concentration (DC/C) as a function
of the dose. The CV% was calculated using the same software.
2.6. Hair samples
Three Holando-Argentino steers aged 2.5 to 3 years old and approximately 450 kg
were used in the experiment. Their phenotype is of white hair with wide regions of
black hair. Two of them were treated by intravenous injection of 10 ml of a veterinary
formulation, 1.95 mg of clenbuterol according to protocol instructions. The animals
were grass-fed and had free access to water. After 25 days, black hair samples were
taken from the animal’s back. All samples were kept at 48C until analysis.
This experiment was performed in compliance with the relevant laws and
institutional guidelines approved by the authorities of the Instituto Nacional de
Tecnologı́a Agropecuaria (INTA), Argentina.
2.7. Sample preparation
Bovine hair samples were washed with 1% of SDS and rinsed with water. After
drying, 100 mg of sample was heated with 2.5 mL of 5 M NaOH for 10 min at 958C.
When the samples reached room temperature, 3 mL of t-butylmethylether was
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added. The mixture was stirred by vortex, incubated for 15 min in ultrasonic bath
and mixed by rotation for another 15 min at room temperature. The last two steps
were repeated and the organic phase was collected and evaporated to dryness
(Haasnoot, Stouten, Schilt and Hooijerink, 1998). The residue was dissolved in
methanol and diluted (1:10) in EIA buffer.
3. Results
3.1. Clen-BSA conjugate and antibody production
The best ratio for the conjugation of clenbuterol to BSA was 0.5 mg of diazo-
clenbuterol to 6 mg of BSA. Immunogenicity is determined by its chemical
structure and the immune system capability to react and produce antibodies. Small
molecules have to be coupled to proteins to facilitate this immuno-reaction. To
obtain antibodies against clenbuterol, rabbits were immunised with already
prepared clen-HSA conjugate. HSA in the antigen would avoid cross-reaction of
the serum to the BSA in the CBB conjugate used in the EIA. The serum obtained
was tested against clen-BSA and clen-HSA by immunodiffusion in agar. Bands of
precipitation with both antigens indicated that antibodies in the serum can
recognise clenbuterol residues in the clen-BSA and clen-HSA molecules. After
purification, the IgG fraction containing 2.7 mg/mL of protein was used in the
following experiments.
3.2. CBB conjugate
The purpose of designing this conjugate was to obtain a molecule with two binding
moieties: a clenbuterol reactive to antibodies, and a biotin to bind avidinenzyme
complexes. The number of relative enzymes bound to the conjugate would
determine the degree of signal amplification. Our first attempt was to couple
directly NHS-biotin to clenbuterol. This reaction did not produce a derivate with
the two moieties useful for an assay (data not shown).
The coupling reaction of diazo-clenbuterol to BSA is achieved by tyrosine
phenolic groups of the protein. NHS-Biotin reacts any primary amine-containing
molecule to attach the biotin label via a stable amide bond, then this reaction enabled
simple and efficient biotin labelling of the protein-clenbuterol conjugate (Figure 1).
This synthesis was carried out six different times with similar performance for CBB
obtained in the titration curves.
A conjugate for wide use in EIAs must fulfil the following requirements:
chemical purity, stability, reproducible antigen-biotin ratio and active binding to
avidinenzyme complexes, which are commercially available and suitable for the
amplification of the signal.
The EIA finally designed is schematised in Figure 2(a). A preliminary competitive
EIA experiment was performed with CBB synthesised with 100 mg of NHS-biotin.
Signal reduction was observed in the presence of clenbuterol in the incubation media,
indicating immunospecific reaction to clenbuterol residues in CBB (Figure 2(b)).
The conjugates coupled with different amounts of NHS-biotin were titrated in
the same range of dilutions for comparison (Figure 3). For this experiment, strips
were prepared with anti-clen at a 1:2000 dilution of the serum.
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The signal increased with the highest number of biotin coupled to the conjugate
within the range of 10100 mg. At higher quantities of NHS-Biotin in the reaction, a
saturation effect could be seen. It could not be established whether this limit was due
to saturation of available sites for biotinylation of the BSA, or steric hindrance for
the binding of many EAP molecules on the conjugates. Thereby, CBB synthesised
from 100 mg of NHS-biotin was the conjugate chosen for the following experiments.
It was used at 1:6000 dilution (1.1 104 mg/mL), corresponding to the middle point
of the curve.
The anti-clen was titrated at those conditions. The better dilution that assured
maximum signal displacement in the presence of 100 ng of clenbuterol per well was
1:2000 from the serum (2.7 103 mg/mL of protein) (data not shown).
3.3. EIA, calibration curve
In Figure 4, a calibration curve in the range from 100 to 0.0064 ng/100 mL
clenbuterol per well is shown. Strips were covered with anti-clen (1:2000) and CBB
Figure 2 (a). Competitive EIA. Clenbuterol competes with CBB for antibody binding,
followed by incubation with EAP. The antibodyCBBEAP complex is finally detected by
pNPP colour reaction. b. Effective antibody-CBB reaction. Strips were prepared with anti-clen
at two different serum dilutions (1:2000 and 1:1000), and reacted with 100 mL of 15 ng/mL
CBB and 100 mL of either buffer or 20 ng/100 mL clenbuterol.
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was used at 1:6000 dilution. The addition of 10% methanol in the standard solutions
changed the IC50 from 0.33 ng/100 mL to 0.44 ng/100 mL. This finding is very
important, especially in residue analysis, where laborious sample preparation
procedures, which usually end in methanol extracts, are usually required.
3.4. Specificity
At the established conditions, the EIA was tested for specificity. The cross reactivity
of different agonists to the anti-clen antibody in the EIA is summarised in Table 1.
The antibody showed very small cross-reaction with the endogenous agonist
epinephrine. However, the affinity for clenbuterol was 500 times higher.
3.5. Calibration curve and precision assay
An average curve resulting from nine independent calibration curves in duplicate was
obtained. Its parameters are the following: A 0.985, B 0.722, C 0.525 and
(a)
(b)
Figure 3 (a). Titration curves of different CBB coupled with 300, 100, 35 and 10 mg of NHS-
Biotin. The curves depicted the average of two different experiments. (b). Maximal absorbance
of experiments depicted on Figure 3(a). vs. microgram of NHS-Biotin.
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D 0.013, with R2 0.999. Then, the limit of detection and the calibration graph
mid-point were estimated at 6.4 and 525 pg per well, respectively.
The CV% of each point was obtained by the average of CV% of dose-response
curves from nine experiments in duplicate. The CV for the calibration curve of the
assay was minimum at the IC50 (0.52 ng/100 mL), and increased at concentrations
higher than 10 ng/100 mL and lower than 0.001 ng/100 mL (Figure 5). The range of
the curve with a CV lower than 20% was observed between 0.1 and 8 ng/100 mL or
between 100 and 8000 pg per well.
Figure 4. Typical calibration curves for clenbuterol by EIA. The strips were prepared with
anti-clen (1:2000). The incubation well contained 100 mL CBB (1:6000) and clenbuterol from
zero to 100 ng/100 mL in buffer or in 10% methanol buffer in 200 mL final volume. Each curve
represents the average of three different experiments.
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3.6. Clenbuterol concentration in hair of treated animals
The performance of the assay in typical residue analysis was evaluated. The residue
accumulation in bovine hair samples was analysed after in vivo injection of
clenbuterol as described earlier, and the results are shown in Table 2. After 25
days, significant residues of clenbuterol in hair were observed in the treated animals.
4. Discussion
4.1. Synthesis of biotinylated conjugate and its applicability
The biotinylated conjugate (CBB) described here showed to be very convenient for
several reasons: it exhibits specific reaction to the antibody, its synthesis and
purification are simple and reproducible, and it is stable for months at 48C. The
coupling of clenbuterol and biotin to BSA at the conditions here described assures
both the reaction antigenantibody and the avidinbiotin complex (Figure 1). NHS-
activated biotins react efficiently with primary amino groups to form stable amide
bonds. Proteins have primary amines in the side chain of lysine residues and N-
terminus. The manufacture’s procedure for biotinilating proteins ordinary will yield
incorporation of 35 or more (812) biotins per molecule of protein, especially when
greater molar excess of biotin reagent was used. BSA molecular weight is about 66
KDa, and is composed of nearly 600 amino acid residues from which 60 are lysine
residues. In present experiment, 20-, 70-, 200- and 580-fold molar excess of biotin
Figure 5. Precision profile. Calibration curve and CV calculated from nine different assays
run in duplicate.
Table 2. Clebuterol concentration in bovine black hair.
Animals A (control) B C
Clenbuterol concentration 292 ng/g 10792 ng/g 4991 ng/g
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were used in the labelling reactions, that means 0.3, 1, 3 and more than ninefold
molar excess of lysine in the CBB10, 35, 100 and 300. On the other hand, random
biotinylation of lysine residue can greatly alter the functional properties of the
molecule or its capacity to be recognised by an antibody. In our case, by increasing
the NHS-biotin in the coupling reaction, a correlation in the amplification effect
could possibly be seen due to an increased number of biotin residues coupled to the
protein in the conjugate. At higher concentrations of biotin, steric hindrance of the
extra-avidin (EAP) enzyme complex could be responsible for the saturation effect.
The exact number of residues of clenbuterol and biotin in the CBB molecule has not
been established at this stage of the research. However, the performance of conjugate
in the assay showed clearly the two functional moieties rendering an amplification
effect.
4.2. The antibody
The specificity of the antiserum was characterised by the evaluation of its cross-
reaction with different agonists, being more active with clenbuterol. In the assay
developed, the endogenous agonist epinephrine had to be 500 times higher than
clenbuterol to obtain the same signal. This is particularly important for the assay
of clenbuterol in tissues where epinephrine could be present. Biotinylated
b-adrenergic agonists have been developed and used in an EIA for clenbuterol
by Rinke and Dürsch (1991). In that experiment, free clenbuterol in the sample
prevents biotinylated salbutamol binding to the anti-clenbuterol antibody. In that
situation, the assay fails to disguise salbutamol from clenbuterol. In our case, the
specificity of the antibody and the appropriate biotinylated conjugate reduced
interferences.
4.3. EIA procedure
The most important components of immunoassays are antibodies and conjugates
which determine assay quality. The antibody coupled to the solid phase showed
effective affinity reaction to the antigen and the conjugate. Several conjugates have
been previously described for antigen and biotin acting as a bridge for EIA (Lacorn,
Fleischer, Wiling, Steinhart, & Claus, 2005; Mares, DeBoever, Stans, Bosmans, &
Kohen, 1995). These conjugates are of defined chemical structure, but, since there is
only one residue for biotinylation, there is no amplification effect as the one
described here. The use of BSA did not allow an exact calculation of the biotin
residues per molecule of reactive clenbuterol. However, under controlled conditions,
a reproducible degree of amplification could be achieved.
Our assay is based on chained affinity reactions: antibody-clenbuterol,
biotin-EAP. It was demonstrated to be useful in a wide range of concentrations
avoiding sample dilutions.
At the IC50 0.52 ng/100 mL, a change to 0.57 ng/100 mL 10% in clenbuterol
concentration implies a response change from 0.500 to 0.483, which is perfectly
detected by a conventional EIA reader. The method described here was able to detect
clenbuterol residues 25 days after a single dose of 1.95 mg clenbuterol per animal.
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5. Conclusion
The continuous development of methods for residue analysis and physiological
determinations is needed. The high detection limit of an immunoassay is sometimes
accompanied with cross-reactions or unpredictable matrix effects. The present EIA
showed to be sensitive, specific and robust, owing to a specific antiserum, a
biotinylated conjugate with signal amplification ability and an appropriate design
that minimised interferences. Although the EIA is a well-known technique, the
design presented here led to an assay with improved stability and simplicity.
In the development of an immunoassay for small molecules, it is necessary to
couple the molecule to proteins in order to function as immunogen for antibody
production. Here, a novel approached for amplification in EIAs has been shown: the
hapten clenbuterol was coupled to BSA which was later biotinilated. Therefore, a
bi-functional conjugate was obtained, both reactive to an antibody and an enzymatic
system. The use of this conjugate in an EIA was presented. This design would not be
restricted to a particular signal and could be used in combination with a variety of
commercially available products such us fluorescence probes, particles for electron
microscopy and both soluble and insoluble enzyme products. This design could also
be applied in other assays like immunosensors, immunocytochemistry and even cell
sorting. Moreover, the signal amplification effect obtained with this bi-functional
conjugate could be useful in other binding reactions such as receptor assays.
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